MyChesCo on MSN

Johnson & Johnson submits FDA application for IMAAVY in WAIHA

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of IMAAVY ...

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus ...

Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S.

Today Kedrion Biopharma announced the nationwide commercial availability of QIVIGY, its FDA‑approved 10% Intravenous Immunoglobulin (IVIG) therapy, through a broad U.S. distribution model designed to ...

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
Morning Overview on MSN

Blood of centenarians reveals 37 proteins that could slow aging

Swiss researchers studying the blood of people who lived past 100 have pinpointed 37 proteins that appear to distinguish centenarians from both younger healthy adults and older hospitalized patients, ...